Life Science Intelligence

The Cypher Solution is simply the best method to visualize the sedimentation of red blood cells during surgery or childbirth by quickly viewing red blood cell sedimentation in a container. Hospitals can quickly and easily visualize red blood cell sedimentation as it is occurring. For more details watch this video:  https://www.lifesciencemarketresearch.com/videos/chris-carew-cypher-medical-scott-pantel-studio-interview-lsi-usa-25

Pretika Medical is modernizing wound care management with “Connected” technology. An enabled medical device system and digital health technology. Integrating with EHR, our Connected Wound Care Technology uses an embedded Advanced Imaging, Sensor and Data Analytic Device for Post-Surgery Healing remotely or in-person without having to remove the surgical dressings, bandages, wraps or casts. For more details watch this video:  https://www.lifesciencemarketresearch.com/videos/thomas-nichols-pretika-medtech-studio-interview-lsi-usa-25

Helmed by CEO Andrew Cleeland, Fogarty Innovation is carrying forward the legacy of Thomas J. Fogarty, MD, by nurturing the next generation of medtech innovators. Blending mentorship, education, and collaboration, and fresh off of its newly announced merger with the Cardiovascular Research Foundation and the awarding of the first Thomas J. Fogarty Innovation Prize, the organization has become a catalyst for global, purpose-driven medtech innovation. Cleeland’s own personal journey from a working-class childhood in Australia to leading billion-dollar startups and now guiding a global nonprofit reflects the same values at the heart of Fogarty Innovation and his deeply human approach to coaching innovators. When you walk into Fogarty Innovation ’s offices in Mountain View, CA, you can feel the pulse of invention. The walls tell stories of prototypes that became lifesaving devices, of startups that grew into category-defining companies, and of founder Thomas J. Fogarty, MD , the pioneering...

Under the direction of Founder and Managing Director Dr. Subhasis Banerji, SynPhNe is bringing a groundbreaking paradigm shift to neurological rehabilitation. With its FDA-cleared, wearable neuro-integrative platform, the company is enabling stroke and brain injury survivors to restore function years beyond the standard recovery window. “SynPhNe digitally restores independent living to those affected by stroke or brain injury,” said Banerji. “It trains brain and muscle in one integrated wearable system, bringing enhanced outcomes, access, and affordability to the doorsteps of those who need it the most.” Origin Story The invention of SynPhNe began with Banerji’s own recovery from a life-altering brain injury. “I beat all odds to make a full recovery after the medical community had given up,” he said. “In the course of this recovery, I realized there is a powerful brain plasticity route to recovery, a paradigm that could change how therapy has been traditionally done for the past 150 ye...

Under the direction of Founder and CEO James Dacombe, CoMind is advancing a new era in neuromonitoring with its non-invasive optical sensing technology for measuring cerebral blood flow (CBF), intracranial pressure (ICP), and other vital brain health indicators, including cerebral autoregulation. With more than $100 million in funding and clinical trials already underway, CoMind is pushing toward FDA approval and a commercial launch in 2027. Origin Story The idea for CoMind was sparked by personal tragedy and a deep sense of curiosity. Dacombe founded the company at just 17 years old after witnessing the toll of neurological conditions on loved ones. “Personal experiences with family members affected by strokes and dementia inspired my interest in exploring how technology could make a difference,” he said. “Many of today’s major health challenges, including mental health disorders, Alzheimer’s, and dementia, as well as systemic issues within hospitals, can be traced to our limited unde...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, announce an acquisition agreement, and much more on the road to LSI USA ’26 in Dana Point (March 16–20). Adagio Medical Appointed longtime Medtronic executive Sean Salmon to its Board of Directors, where he will also serve on the audit and compensation committees. Salmon’s deep operational experience and electrophysiology expertise will support Adagio as the company advances its ultra-low cryoablation technology for ventricular tachycardia. CathVision Appointed former Boston Scientific EMEA President Eric Thepaut as independent Chairman of the Board and released Version 3.5 of its ECGeniusⓇ System. The update adds hardware and software enhancements designed to improve workflow efficiency and system performance as the company prepares for commercial growth in the U.S. and Europe. CMR Surgical Announced that it has received FDA 510(k) clearance for Versi...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, receive regulatory approvals, achieve clinical milestones, and much more on the road to LSI USA ’26 in Dana Point (March 16–20). AccuLine Welcomed LSI Alumni Joe Mullings to its Advisory Board, bringing one of the most connected and trusted leaders in global medtech to support the company’s growth. Mullings’ strategic guidance and industry-wide reach will help AccuLine scale its CORA platform in the U.S. and advance toward its Series A. Akura Medical Announced a $53M first close in its Series C financing to advance development of the Katana™ Thrombectomy System and NavIQ™ quantification software. The funding will also support completion of QUADRA-PE enrollment, regulatory submissions, and the establishment of a joint venture in Qatar. Atraverse Medical Secured FDA 510(k) clearance for its fully integrated HOTWIRE™ Transseptal Access System, which includes the HO...

CathWorks is redefining what a medtech partnership can be through a deliberate, globally minded build-to-buy model aimed at transforming how coronary artery disease is diagnosed and treated. Anchored by its “skin-in-the-game” partnership with Medtronic and its innovative wire-free and drug-free FFRangio System, the company has used markets across the United States, Europe, and Japan as real-world validation engines. The result is a model that combines scientific proof, speedy innovation, scalability, and partnership discipline that could impact how startups position themselves for acquisition. When Ramin Mousavi , President and CEO of CathWorks , steps onto an LSI stage, he likes to mention that CathWorks was the very first company to present at the very first LSI Emerging Medtech Summit, in 2020. It’s an aside delivered with a smile, and is not so much nostalgic but rather a celebratory reflection backed up by 12+ years of startup peaks and valleys, and a game-changing build-to-buy de...